The company operates in a single reportable segment (API/Bulk Drugs). Revenue for FY2024 was INR 397.65 Cr, representing a 5.09% decline from INR 418.96 Cr in FY2023. However, 9MFY...

Therapeutic-wise revenue within the API segment for Q2 FY26: Anti-biotic (36.1%), Anti-protozoal (18.8%), Anti-diabetic (15.3%), Anti-inflammatory (11.8%), Anti-fungal (11.7%), and...

No documents found

The company operates in a single segment (Pharmaceuticals) as per Ind AS 108; no separate segment information is provided. Total revenue for FY2024-25 was INR 661.51 Cr, representi...

Consolidated revenue grew 13% YoY to INR 203.6 Cr in H1 FY26. Segment growth: Domestic Own Brands grew 21% YoY (INR 69.4 Cr), CDMO grew 8% YoY (INR 79 Cr), International/Exports gr...

Consolidated total income for H1 FY26 rose to INR 5,389 Cr, a 16% increase from INR 4,640 Cr in H1 FY25. In Q2 FY26, the revenue mix shifted significantly toward Custom Synthesis, ...

Total revenue for FY25 reached INR 1,859.8 Cr, a 4% YoY increase. The Pharmaceutical segment grew 7.1% YoY to INR 816.8 Cr in 9M FY25, while the Crop Protection segment faced headw...

Consolidated revenue from operations grew 14.78% YoY to INR 155.71 Cr in FY25. H1FY26 revenue grew 1% YoY to INR 84.05 Cr, indicating a stabilization in sales volume despite global...

Consolidated revenue for Q2'FY26 grew 12% YoY to INR 1,966 Cr, driven by the new third line in CDMO Sterile Injectables and growth in Radiopharma, Allergy Immunotherapy, and CRDMO....

Total revenue from operations fell 14.1% YoY to INR 43.31 Cr in FY25 from INR 50.42 Cr in FY24. Segment-specific growth percentages are not disclosed in available documents.

In Q2 FY26, Animal API contributed 90% of revenue (down from 94% in Q2 FY25), Human API 4% (up from 3%), Intermediates 5% (up from 2%), and Formulations 1% (down from 2%). Overall ...

The CMS (CDMO) segment now contributes over 50% of total revenues. Overall operating income for FY25 was INR 1,476.84 Cr, representing a 5.2% decline from INR 1,558.58 Cr in FY24. ...

The API segment, which currently contributes over 99% of total revenue, grew 5.6% YoY in FY25. Revenue for the quarter ended September 30, 2025, was INR 28.66 Cr.

The Anti-Retroviral (ARV) segment saw a significant recovery, increasing its revenue contribution to 20% in FY24 from just 3% in FY23. Ibuprofen revenue grew 1.6x in FY24. Overall ...

The company operates in a single segment: manufacturing of pharmaceutical products. Revenue from operations for H1 FY26 (half-year ended September 30, 2025) grew by 115.08% YoY to ...